Biocon has informed that the company and HCG group of hospitals today announced their partnership to conduct a study to evaluate the potential benefits of BIOMAb EGFR in cervical cancer patients. This unique molecule would take healthcare for cervical cancer patients to a new threshold. BIOMAb EGFR is Biocon`s humanized monoclonal antibody which is approved for the treatment of head and neck cancers in India.
The study will be conducted for six years in various centers of HCG across the country, involving many eminent oncologists and will be in compliance to ICH-GCP guidelines. The participating centers are Bangalore, Mysore, Vijayavada, Ranchi, Cuttack and Nashik.
Source :www.biginfotech.in
No comments:
Post a Comment